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Glycome modulations have been described in the onset and progression of many diseases.
Thus, many studies have proposed glycans from blood glycoproteins as disease markers.
Astonishingly, little effort has been given unraveling preanalytical conditions potentially influ-
encing glycan analysis prior to blood biomarker studies. In this work, we evaluate for the first
time the effect of hemolysis, storage and blood collection, but also influence of various times
and temperatures between individual processing steps on the total N-glycome and on a gly-
can-biomarker score. Venous blood was collected from 10 healthy donors in 11 blood collec-
tion tubes with different additives, processed variously to obtain 16 preanalytical variables
and N-glycans released from serum or plasma were analyzed by MALDI-TOF-MS and capil-
lary electrophoresis coupled with fluorescence detection (CE-LIF) for the first time. Long
time storage of deep frozen samples at -20˚C or -80˚C exerted only a minor influence on the
glycome as demonstrated by CE-LIF. The N-glycome was very stable evidenced by MALDI-
TOF when stored at 4˚C for at least 48 hours and blood collected in tubes devoid of addi-
tives. The glycome was stable upon storage after centrifugation and aliquoting, which is an
important information considering future diagnostic applications. Hemolysis, however, nega-
tively correlated with an established glycan score for ovarian cancer, when evaluated by
MALDI-TOF-MS measurement by affecting relative intensities of certain glycans, which
could lead to false negative / positive results in glycan biomarker studies.
Introduction
With the exception of albumin, most abundant serum and plasma proteins are co- and post-
translationally glycosylated with N- and O-glycans [1]. Protein glycosylation effects various
biological roles such as prolongation of protein half-life due to reduced clearance and protec-
tion from proteolysis [2, 3]. In addition, it also mediates the interaction of proteins with gly-
can-specific receptors in the context of a wide variety of cell functions, for instance cell-cell
communication, signal transduction or immune response [3–6]. The glycans of serum and
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plasma glycoproteins are referred to as the serum and plasma glycome. In recent years,
research has shown that not only the monosaccharide composition, but also the structure of
the N- and O-glycans of serum and plasma glycoproteins is modulated under pathological
conditions. This includes genetic diseases [7], acute and chronic inflammation [8–10] and
malignant diseases such as colon and ovarian cancer [11–13]. In the past decades, glycan anal-
ysis has been hampered by time-consuming analytical procedures. Recently, methods for
high-throughput analysis have been developed that allow the investigation of large numbers of
samples [11, 14, 15]. A growing number of studies established that changes in glycome are not
only of pathogenic importance, but can be used as diagnostic biomarkers. In particular, gly-
come variations are a hallmark of malignancy with glycome modulations being cancer-specific
or -associated [16–21]. Such a glycan-based cancer biomarker, the GLYCOV index score,
developed in our laboratory, combined qualitative and quantitative changes of serum glycome
in patients suffering from epithelial ovarian cancer [11, 12]. Its sensitivity and specificity were
compared with that of the established tumor marker CA125 and indicated superior accuracy,
even for early-stage patients.
The analytical methods used to study the glycome are very well established; MALDI-TOF-
MS, capillary electrophoresis coupled with fluorescence detection (CE-LIF) and HPLC being
among the most used technologies [15, 22]. Intra-individual stability of the glycome in time
has been well studied, demonstrating the influence of the lifestyle, medication or environmen-
tal factors [23, 24]. It was reported by Ventham et al.[25] that, when a standard processing
methodology is used, variables such as tube manufacturer, tube volume and addition of separa-
tion gel as well as centrifugation time, temperature and speed, have little effect on results of
HPLC measurements of human serum N-glycome. Another report by Adamczyk et al.[26]
described that N-glycome differences between serum and plasma are caused mainly by fibrino-
gen N-glycosylation and that the presence or absence of anticoagulant does influence results of
HPLC glycan analysis regardless of anticoagulant type. Although there have been about 15,000
entries in PubMed for glycan biomarkers in the past ten years, the preanalytical conditions of
MALDI-TOF-MS and CE-LIF glycome analysis have never been reported in detail. However,
preanalytical variables may impact significantly glycome profiles and can lead to inaccurate
results as reported for peptide profiling [27–29]. It can be assumed that the activity of exogly-
cosidases and glycosyltransferases that are detectable in serum such as sialidase, mannosidase
and sialyltransferase, will depend on the temperature of the sample and the time until storage
and/or measurement. As for proteomics [27, 28], the influence of sample freezing could also
lead to glycan degradation. Moreover, glycoproteins may be released during the preanalytical
phase from intracellular organelles or by shedding of the cell surface of leukocytes and erythro-
cytes, which would result in changes of the serum glycome. With the increased popularity of
international and multi-center studies [22, 30–32], it becomes necessary to evaluate the effect
of pre-analytical conditions that are more difficult to control and standardise, such as time
periods between individual processing steps, which depend greatly on the method of transpor-
tation. For example, transportation from collection site to processing laboratory can greatly
differ. On-site laboratories have the advantage of complete control over preanalytical process,
while courier pick-up and pneumatic tube system introduce variables such as delivery times,
temperatures and physical damage. In general, higher occurrence of hemolysis was reported
for samples transported by pneumatic tube system, but this differs from system to system [33,
34]. To our knowledge, there is no research published on the effects of hemolysis on the results
of N-glycome analysis, namely individual glycans and glycan scores. In this work, we evaluate
for the first time not only the effect of hemolysis, storage and blood collection, but also influ-
ence of various times and temperatures between individual processing steps on the N-glycome
using blood samples from healthy volunteers and detection with MALDI-TOF-MS and
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CE-LIF methods. Additionally, we study the influence of preanalytical conditions not only on
single glycan structures but also on a glycan-based ovarian cancer biomarker GLYCOV [11],
which is an index score built from the relative intensities of eleven glycan structures.
Materials and methods
Blood sampling procedure
Blood from 10 healthy female donors (20–30 years) was collected according to the ethical
approval of the Charite´ Medical University EA1/175/14 in eleven different collection tubes per
donor. All collection tubes were S-Monovette tubes (Sarstedt, Germany) (Table 1). Plasma
samples were collected in five tubes containing either K3 EDTA (n = 1, Tube I), trisodium cit-
rate solution (n = 3, Tubes G, H, K) or heparin (n = 1, Tube J). Six serum samples were col-
lected using 5 tubes containing clotting activating silica-covered beads without separation gel
(Tubes A-D) and one tube with separation gel (Tube E). To evaluate the influence of the collec-
tion method, one evacuated blood collection tube was used for collection of citrated plasma
sample (Tube G), the 10 other tubes were collected by free flow. The blood collections were
performed in two sets of five donors six months apart. The second collection was performed
after initial data analysis and one additional condition was tested.
Blood preanalytical processing
Samples were kept in an up-right position except during centrifugation. Tubes were further
processed to generate a total of 16 different conditions (Fig 1). Reference plasma and serum
samples were collected in a trisodium citrate tube (tube H) and a serum clot activator tube
(tube F), respectively. To evaluate the influence of delayed centrifugation, three collection
tubes were kept at room temperature (RT) for 2 h and 6 h, or at 4˚C for 2 h (tubes A, B and C,
respectively). Seven tubes (tubes D-J) were left for 30 min at RT and were then centrifuged at
1500×g at 4˚C for 15 min. Collection tubes D and E (clotting activator and clotting activator
with separation gel) were left at RT for 6 h after centrifugation. The last tube (tube K) was used
to induce two hemolytic conditions before centrifugation. Additionally, for the second collec-
tion set (n = 5), one milliliter of citrated whole blood from the same tube was aliquoted and
shaken in 1.5 ml polypropylene tubes placed in an up-right position on a Thermomixer com-
fort (Eppendorf, Hamburg, Germany) at maximum speed of 1400 rpm overnight at RT to test
extreme deviations from standard preanalytical procedures. The remaining citrated blood was
hemolysed directly in the collection tube using hypotonic conditions by addition of deionized
water (MilliQ, Millipore) for all ten donors in both sets. Hemolysis was confirmed visually for
both samples hemolysed by hypotonic conditions (n = 10) and by mixing (n = 5), and free
hemoglobin was measured to quantify the degree of hemolysis. Two hundred microliters of
each sample were then aliquoted and stored at -80˚C or -20˚C.
Table 1. List of serum and plasma collection tubes used in this study.
Tube Nr. Tube Tube material Separator Clot activator Anticoagulant
A-D S-Monovette1 4.9ml Z Polypropylene (PP) None Silicate coated beads None
E S-Monovette1 4ml Z-Gel Polypropylene (PP) Polyacrylic ester gel Silicate coated beads None
F S-Monovette1 9ml Z Polypropylene (PP) None Silicate coated beads None
G-H, K S-Monovette1 5ml 9NC Polypropylene (PP) None None Trisodium citrate solution 3.2% (1:10)
I S-Monovette1 4.9ml K3E Polypropylene (PP) None None K3 EDTA
J S-Monovette1 4.9ml LH Polypropylene (PP) None None Lithium heparin
https://doi.org/10.1371/journal.pone.0200507.t001
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N-Glycan release and purification
All samples were subjected to glycomic profiling as described in a previous study by Biskup
et al. without any modification [11]. Briefly, N-glycans were released and isolated from 10 μl of
sample, e.g., the serum/ plasma was diluted in phosphate buffer (pH 6.8), reduced with dithio-
erythritol (DTE; Sigma-Aldrich) and alkylated with iodoacetamide (IAA; Sigma-Aldrich).
Samples were prepared in triplicate. Excess of DTE was used to stop the reaction and 100 mU
of Peptide-N-glycosidase F (PNGase F; EC 3.5.1.52; Roche Applied Science, Indianapolis, IN)
were used for N-glycan release at 37˚C overnight. Samples were purified using C18 cartridges
and desalting was performed by graphitized carbon columns (both purchased from Alltech,
Deerfield, IL).
Mass spectrometry
Permethylation was performed as published by Wedepohl et al. [35]. After termination of the
reaction, permethylated glycans, purified by chloroform extraction, were washed with water
until the pH of the aqueous phase was neutral. Chloroform was removed under reduced atmo-
sphere, the sample dissolved in 5 μl 75% aqueous acetonitrile and 0.5 μl of the sample was
mixed with 0.5 μl 10 mg/ml super DHB matrix (2-hydroxy-5-methoxy-benzoic acid and
Fig 1. Flowchart showing the preanalytical processing carried out in this study. Reference conditions (time frames between processing steps as short as
possible) are marked in red. Samples were kept for 30 min at RT, were subsequently centrifuged for 15 minutes at 1500×g and 4˚C, aliquoted immediately after
centrifugation and stored at -80˚C, unless stated otherwise. Conditions 1–15 were created for the first set of collection, conditions 1–16 were created for the
second set of collection. It should be noted that tubes F and K were used for generating multiple conditions.
https://doi.org/10.1371/journal.pone.0200507.g001
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2,5-dihydroxybenzoic acid, 1:9; Sigma-Aldrich), prepared in 10% acetonitrile, 90% water, on a
ground steel MALDI target (Bruker Daltonics, Bremen, Germany) and used for MALDI--
TOF-MS measurement. Spectra were recorded in a reflectron positive mode on an Ultraflex
III mass spectrometer (Bruker Daltonics, Bremen, Germany) equipped with a Smartbeam
laser. A glucose ladder was used for calibration and 2000 laser shots were recorded for each
spectrum in the mass range 1000–5000 Da with ion suppression below 990 Da (100 Hz laser
frequency). The accelerating voltage was 25kV. Based on the knowledge of N-glycan biosyn-
thetic pathways and specificity of PNGase F, all N-glycans were presumed to have N2H3 core
structure and the compositions (numbers of H, N, F, S) were manually interpreted based on
their m/z values. MALDI-TOF-MS spectra were annotated manually with the assistance of
GlycoWorkBench (version 1.1.3480) glycoinformatic tool and literature [1] and exported
using the Flexanalysis Software (Version 3.0, Build 54, Bruker Daltonics, Bremen, Germany)
as ASCII files. The resulting peak lists were used for targeted data extraction of the area under
the curve after manual recalibration using glycan peaks with known compositions (H3N4F1,
H4N4F1, H5N4F1, H5N4S1, H5N5F1S1, H5N4S2, H6N5S3, H6N5F1S3 and H7N6S4), base-
line detection and subsequent subtraction from intensities of all isotopic peaks using Python
Script published by Reiding et al. [36] with permethylated masses as building blocks (S1
Table), sodium as charge carrier and a calculation window of 0.49 m/z. Complete MALDI--
TOF-MS data are presented in S1 File.
Capillary electrophoresis
Samples were chemically desialylated with 0.5 M acetic acid at 80˚C for 3 h and 8-aminopyr-
ene-1,3,6-trisulfonic acid (APTS) derivatization was performed as described earlier [37]. A
Beckman P/ACE MDQ system equipped with LIF detection (λex = 488 nm, λem = 510 ± 10
nm) (Beckman Coulter, Fullerton, CA, USA) was used to perform CE separations of APTS-
labeled N-glycans by reversed polarity on a polyvinyl alcohol-coated capillary (Beckman,
50 μm I.D., total capillary length and effective separation length from the injection to the
detector were 65 cm and 50 cm, respectively). Samples were injected for 10 s at a pressure of
0.5 psi and separations were performed using an applied potential of 30 kV for 20 min at 25˚C.
APTS-labeled maltose was used as an internal standard. Signals from CE-LIF measurements,
exported as ASCII files, were aligned using a Python script HPACED [38] based on the highest
peak of the spectrum. The software OpenChrom (Community edition 1.1.0) was used to per-
form baseline subtraction, signal smoothing and signal integration, which was automatically
performed using the Peak Detector integration function. Complete CE-LIF data are presented
in S1 File.
Statistical analysis
SPSS for Windows, version 21 (SPSS Inc, Chicago, Ill) was used for statistical analysis. All sam-
ples were prepared in replicates (n = 3 for MALDI-TOF-MS, n = 2 for CE-LIF) and their
means were calculated. Shapiro-Wilk normality test showed non-normal distribution of some
glycans, therefore non-parametric tests were used to assess differences between conditions.
Friedman’s non-parametric test was used on the complete data set (all conditions from 10 per-
sons) to test if there were differences in relative intensities of individual glycans between differ-
ent preanalytical conditions and p values< .05 were considered statistically significant. Post-
hoc analysis with Wilcoxon signed-rank tests was performed with a Bonferroni correction
applied, therefore significance levels were set at p < .0056 (n of comparisons = 9) for serum
conditions and p < .01 (n of comparisons = 5) for plasma conditions.
Preanalytical processing impacts on human N-glycome
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Results
N-Glycan profiles obtained with standard conditions
The total serum and plasma N-glycome profiles of 10 healthy women with age 20–30 years,
collected in various blood collection tubes and processed to obtain 16 different conditions,
were analysed in triplicates, leading to 465 samples total, of these 60 were obtained from refer-
ence serum and plasma test tubes. Reference conditions were set in such a manner that the
time frames between processing steps such as centrifugation and aliquoting were as short as
possible, namely 30 min between blood collection and centrifugation, followed by immediate
aliquoting and storage. N-Glycans were released by PNGase F digestion from reduced and
alkylated proteins. They were subsequently purified, permethylated and finally measured by
MALDI-TOF-MS. An exemplary annotated spectrum obtained from reference serum tube F is
shown in S1 Fig.
Four of the detected N-glycans were high-mannose structures, seven fucosylated asialylated
complex-type glycans, fourteen were complex-type glycans partially or fully capped with sialic
acids and fourteen were fucosylated complex N-glycans with sialic acids (S2 Table).
Relative intensities of 46 glycans (H = hexose, N = N-acetylhexosamine, S = Sialic acid,
F = fucose), normalized to the sum of all glycans and means were calculated for triplicates
(n = 465, Fig 2). The majority of the detected N-glycans was of complex-type (93.6% ± 3.7,
93.2% ± 2.8; mean ± SD for reference plasma and serum, respectively), followed by high-man-
nose (5.7% ± 3.5, 6.2% ± 2.6) and hybrid-type (0.7% ± 0.3%, 0.6 ± 0.2). Further differentiation
of complex type N-glycans showed that diantennary N-glycans were the most abundant struc-
tures (72.5% ± 5.1, 72.8% ± 4.2; mean ± SD for reference plasma and serum, respectively),
Fig 2. Results of MALDI-TOF-MS analysis. Average MALDI-TOF-MS N-glycan (A) relative intensities from 10 healthy donors under 16 preanalytical
conditions (Fig 1). The serum and plasma standard conditions are marked with thick lines. Small increase of N-glycans having low masses (B) can be
observed for hemolysed samples (condition 16), while N-glycans having high masses show a small decrease (C).
https://doi.org/10.1371/journal.pone.0200507.g002
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followed by triantennary (10.1% ± 3.6, 9.3% ± 4.0), monoantennary (6.9% ± 3.1, 6.9% ± 3.7)
and tetraantennary (0.9% ± 0.3, 0.7% ± 0.4) N-glycans. Relative intensities of all structures for
standard plasma and serum samples are shown in S3 Table.
N-Glycans were released by PNGase F digestion from human serum or plasma, desialy-
lated, labeled with APTS and measured by CE-LIF (Fig 3). This type of analysis enables the
identification of N-glycan linkage and positional isomers, which is not possible by MALDI--
TOF-MS analysis alone, however, the information about sialylation is lost as sialic acids are
cleaved prior to analysis. Nevertheless, some glycan structures co-migrate by CE-LIF, leading
to 23 glycan peaks. Their relative intensities were determined for each sample and means were
calculated for duplicates (n = 310). The standard Oxford notation style was used for CE-LIF
results due to its simplicity even for more complex structures. Explanation of naming and the
corresponding CFG notations are depicted in S4 Table.
N-Glycan profiling of preanalytical deviations by MALDI-TOF-MS and
CE-LIF
For MALDI-TOF-MS we detected statistically significant differences for relative intensities of
19 glycans, four of those had a relative intensity > 1%. Among those 19 structures, four were
high-mannose structures (N2H5, N2H6, N2H7, N2H8) and four asialylated complex-type
structures (N3H4, N4H3, N4H5 and N5H4). Eight sialylated structures were significantly
different. Five of them were monosialylated (N3H4S1, N3H5S1, N4H4S1, N4H5S1 and
N5H6S1), two disialylated (N4H5S2, N5H6S2) and one tetrasialylated (N6H7S4). We detected
Fig 3. Results of CE-LIF analysis. Average CE-LIF N-glycan profiles (A) from 10 healthy donors under various preanalytical conditions. The conditions are
numbered as mentioned in Fig 1. The serum and plasma standard conditions are marked with thick lines. Relative intensities of lower mass (B) and higher
mass N-glycans (C) show the similar results throughout various conditions.
https://doi.org/10.1371/journal.pone.0200507.g003
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no differences in relative intensities of trisialylated N-glycans. Two fucosylated structures
(N5H4F1, N5H5F2) and only one from fourteen fucosylated sialylated structures (N6H7S4F1)
were significantly different (S3A Table).
For the CE-LIF measurements 19 glycan peaks out of 23 were significantly different accord-
ing to the Friedman’s test, from which ten had relative areas > 1% (S4A Table). It should be
noted that the Friedman’s test detects differences between all the tested conditions, not only
deviations from the standard procedures. Moreover, affected glycans generally had relative
intensities under 1%.
From these results, we can conclude that high-mannose glycans appear to be the most sen-
sitive N-glycans throughout all conditions, while fucosylated sialylated structures remain
rather stable even during improper pre-analytical processing.
Effect of conditions before centrifugation. Three different conditions were used to test
the effect of delayed centrifugation. Samples were kept at up-right position at room tempera-
ture for 2 hours and 6 hours and in the refrigerator (4–8˚C) for 2 hours. We expected to
observe changes caused by the activity of enzymes, such as sialidases. However, we did not
detect any statistically significant change in relative intensities of the tested glycans caused by
the delays in centrifugation when MALDI-TOF-MS and CE-LIF methods were used (S3B and
S4B Tables).
Effect of long time storage and storage temperature. Two different storage temperatures
were tested and compared to the standard preanalytical conditions. MALDI-TOF-MS mea-
surements did not show statistically significant differences for samples stored for a period lon-
ger than 2 months neither at -20˚C nor at -80˚C. However, the CE-LIF measurements
displayed significant differences between the standard serum preanalytical conditions and the
non-standard conditions, namely cFA2BG2 (4.54%, 4.06–5.62), Z = -2.803, p = .005 for two
months long storage at -80˚C, and aF3A4G4 (0.06%, 0.05–0.08), Z = -2.803, p = .005 for two
months storage at -20˚C.
Effect of collection tube additives. There were no significant differences between the
standard serum preanalytical conditions and the non-standard conditions when MALDI-
TOF-MS was used, while the CE-LIF glycan peak containing structures A3G3[3] + A3[6]G3
(1.58%, 1.45–1.73), Z = -2.803, p = .005 was significantly increased for serum gel tube.
MALDI-TOF-MS measurements of plasma samples detected two structures, which were
significantly decreased in EDTA plasma [N3H5S1 (0.43%, 0.31–0.49), Z = -2.803, p = .005;
N5H5F2 (0.28%, 0.14–0.43), Z = -2.803, p = .005] and heparin plasma samples [N3H5S1
(0.37%, 0.27–0.49), Z = -2.803, p = .005; N5H5F2 (0.22%, 0.18–0.40), Z = -2.599, p = .009]
compared to the standard plasma condition.
Additionally, six glycan peaks were significantly different between the standard plasma pre-
analytical condition and heparin for CE-LIF measurements. Three peaks [M3 (0.39%, 0.21–
0.52), Z = -2.599, p = .009; A3G3[3] + A3[6]G3 (1.53%, 1.40–1.70), Z = -2.803, p = .005; and
aFA3G3 (1.82%, 0.77–2.94), Z = -2.701, p = .007] were increased, and three peaks [FA2 + A3
(2.54%, 2.04–2.82), Z = -2.701, p = .007; A2[3]G1 (0.50%, 0.42–0.54), Z = -2.803, p = .005; and
FA2B (0.56%, 0.53–0.64), Z = -2.701, p = .007] were decreased.
Effect of hypotonic conditions on the N-glycome. Mild hemolysis was induced by addi-
tion of deionized water to the sample. We did not detect any statistically significant differences
between hemolysed samples and the reference plasma by MALDI-TOF-MS measurement,
however the sample hemolysed by hypotonic conditions differed from the standard plasma
condition in relative areas of A2B3G1 (0.59%, 0.54–0.62), Z = -2.701, p = .007, which was sig-
nificantly increased, and A3G3 (11.3%, 9.24–13.23), Z = -2.803, p = .005, which was signifi-
cantly decreased (S4B Table) as determined by CE-LIF.
Preanalytical processing impacts on human N-glycome
PLOS ONE | https://doi.org/10.1371/journal.pone.0200507 July 11, 2018 8 / 15
Effect of overnight shaking at RT on the N-glycome. Strong hemolysis was induced in
plasma samples from five donors by extreme conditions, e.g., mixing at 1400 rpm at RT over-
night. We performed Wilcoxon signed-rank tests with Bonferroni correction applied (p< .01)
to compare these samples to standard samples from the same individuals. Although samples
were hemolysed, no statistically significant differences between the relative intensities of glycan
structures were observed neither for MALDI-TOF-MS nor for CE-LIF measurements (see S3C
and S4C Tables).
Correlation between hemolysis and N-glycome. Correlation analysis was performed to
assess the relationship between relative intensities of individual glycans as well as calculated
traits and the degree of hemolysis, which is presented as the concentration of free hemoglobin
in mg/dl. The correlations are described using empirical classifications of interpreting correla-
tion strength by using r proposed by Evans [39]. Two different types of hemolysis (tube K)
were tested: hemolysis by hypotonic conditions (condition 15, n = 10) and hemolysis caused
by combination of factors, e.g. mixing at 1400 rpm at RT overnight (condition 16, n = 5).
We observed a statistically significant very strong negative correlation between relative
intensity of N5H6F1 (r = -.917, n = 5, p = .028) and the degree of hemolysis in samples hemo-
lysed by combination of factors. Even though other structures did not show a significant corre-
lation between relative intensities and concentration of free hemoglobin, there was a highly
significant very strong negative correlation with the value of glycan-based ovarian cancer bio-
marker (GLYCOV) (r = -.958, n = 5, p = .010), which is a score developed in our research
group calculated as the ratio: (sum of relative intensities of (N5H6S3, N5H6S3F2, N6H7S3F1,
N6H7S3F2, N6H7S4F1, N6H7S4F2, N6H7S4F3))/74/(sum of relative intensities of (N2H5,
N2H6, N2H7 and N2H8)) (Fig 4A). It should be noted that none of the glycan structures that
are used to calculate the biomarker GLYCOV showed statistically significant differences
between the standard collection method and hemolysed sample when calculated individually.
Nevertheless, the values of GLYCOV decreased upon hemolysis, which would presumably
lead also to false negative measurements in ovarian cancer patients, indicating that hemolysed
samples should not be considered used for biomarker assessments.
Correlation between hemolysis by hypotonic conditions and N-glycome. In hypotoni-
cally-hemolysed samples we found a statistically significant positive correlation between the
Fig 4. Scatterplot showing the correlation between free hemoglobin concentration and GLYCOV biomarker values. (A) samples hemolysed by mixing
samples, (B) hemolysed by hypotonic conditions. Gray solid and dashed lines indicate the .75 and .95 confidence intervals, respectively. The GLYCOV score
is a glycan score developed to diagnose ovarian cancer as follows: ratio (sum of relative intensities of (N5H6S3, N5H6S3F2, N6H7S3F1, N6H7S3F2,
N6H7S4F1, N6H7S4F2, N6H7S4F3))/74/(sum of relative intensities of (N2H5, N2H6, N2H7 and N2H8).
https://doi.org/10.1371/journal.pone.0200507.g004
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concentration of free hemoglobin and relative intensities of two oligomannose structures and
four asialo complex N-glycans of which two of these are fucosylated. There was a very strong
positive correlation for N2H5 (r = .852, n = 10, p = .002), and a strong positive correlation for
N2H6 (r = .715, n = 10, p = .020), N3H3 (r = .751, n = 10, p = .012), N3H4 (r = .770, n = 10,
p = .009), N4H3F1 (r = .727, n = 10, p = .012) and N4H4F1 (r = .634, n = 10, p = .049)], which
is in agreement with results observed for GLYCOV. There were also strong negative correla-
tions for two N-glycans [N4H5S1 (r = -.695, n = 10, p = .026); N5H6S2 (r = -.667, n = 10, p =
.035)] (S2 Fig). However, there was no statistically significant correlation between the GLY-
COV value and the degree of hemolysis (r = -.404, n = 5, p = .247) (Fig 4B), even though two
structures, which were used for its calculation, e.g., N2H5 and N2H6 showed strong individual
correlation.
There was no statistically significant correlation between relative areas of glycan peaks and
the degree of hemolysis when measured by CE-LIF for neither type of hemolysed samples. It
should be noted that when the glycome is measured by CE-LIF, most oligomannose structures
overlap and therefore cannot be measured distinctly.
Discussion
This study, which investigated for the first time 16 different preanalytical conditions prior to
N-glycan analysis carried out by MALDI-TOF-MS (n = 465 samples) and CE-LIF (n = 310
samples), highlights slight differences that could influence results of glycan biomarker studies.
While intra-individual and longitudinal stability of the glycome and methodological robust-
ness were previously analyzed [22–24], the present study is the unconditional prerequisite
before translating glycan biomarker discovery into clinical chemistry laboratories.
Using MALDI-TOF-MS, it was shown that modulation of oligomannose structures can
occur during pre-analytical processing, which affects glycan biomarkers such as the GLYCOV
score developed in our laboratory [11] as shown in this report. The increase of oligomannose
structures could result from nascent intracellular glycoproteins released during cell lysis [40].
The modulations of complex-type and sialylated glycans could be a result of circulating exogly-
cosidase activity [41, 42]. In this study, in vitro hemolysis was successfully induced by using
extreme conditions after blood withdrawal, while no significant in vivo hemolysis was
observed, since samples were taken from young healthy individuals. It was previously shown
that in vitro hemolysis, one of the leading causes of preanalytical errors, is more likely to occur
when sampling is performed in tubes filled below halfway in individuals older than 63 years
[43, 44].
Using CE-LIF, it was shown that long time storage of deep frozen samples at -20˚C or
-80˚C exerted only a minor influence on the glycome. Results were slightly different from
MALDI-TOF-MS for two reasons. First, sialic acids were not investigated here and second,
most oligomannose N-glycans co-migrate with other human blood N-glycans, preventing
their analysis.
This study demonstrated that the glycome is more robust than other analytes such as
proteins and peptides, for which preanalytical errors lead to non-reproducibility of ground-
breaking publications [45] and to commercial failures in ovarian cancer diagnosis, such as
lysophosphatidic acid as a marker for ovarian cancer [46]. Importantly, Diamandis and
coworkers later discovered that lysophosphatidic acid was leaking from blood cells, thereby
introducing preanalytical biases [47]. Nonetheless, it should be taken into account that our
data were derived from healthy individuals. Thus, preanalytical analyses, as performed in the
present study, are additionally warranted under specified disease conditions.
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In this work, it could be shown that the glycome is rather stable in serum and plasma as
short time delay between centrifugation at various temperatures seemed to have a minor effect
on results. In addition, the glycome was stable upon storage at 4˚C for at least 48 hours after
centrifugation and aliquoting, which is an important information considering future diagnos-
tic applications in clinical laboratories. However, it should be emphasized that hemolysis, a fre-
quently seen clinical phenomenon in routine blood withdrawal procedures, affects relative
intensities of certain glycans, which could lead to false negative (or positive) results in glycan
biomarker studies and facilitate wrong clinical interpretations.
Supporting information
S1 Fig. MALDI-TOF-MS N-glycome profile obtained after PNGase F enzymatic release
from plasmatic proteins, purification and permethylation. Measurements were performed
in positive-ion mode. All ions are present in their sodiated form [M+Na]+. Structures are
depicted following the CFG notation.
(PDF)
S2 Fig. Scatter plots of free hemoglobin concentration and rel. intensities of N-glycans.
(PDF)
S1 File. Complete data of MALDI-TOF-MS and CE-LIF measurements.
(XLSX)
S1 Table. Masses of building blocks used for targeted data extraction by a Python script.
(PDF)
S2 Table. N-Glycans sorted by glycan type.
(PDF)
S3 Table. Results of MALDI-TOF-MS measurements and statistical analysis. Relative inten-
sities of individual N-glycans (median, IQR) were tested for differences between all groups
(n = 15) (a) by Friedman’s test and p-values < .05 were considered statistically significant
(marked in red field). Only the structures, which were detected as significantly different by
Friedman’s test, were further analysed by a Wilcoxon’s pot-hoc test to identify whether such
differences occurred as a result of deviation from the standard procedure. (b) Wilcoxon’s test
was used to compare standard conditions to all the altered conditions for plasma and serum
separately. Statistical tests between two non-standard conditions were not performed, since
these were not relevant for this study. Nine tests were performed for serum conditions, result-
ing in a Bonferroni corrected p value of .0056. For plasma conditions five tests were per-
formed, including (c) Wilcoxon’s test where results from only 5 individuals were compared,
therefore the Bonferroni corrected p value for plasma samples was .01.
(PDF)
S4 Table. Results of CE-LIF measurements and statistical analysis. Relative intensities of
individual N-glycans (median, IQR) were tested for differences between all groups (n = 15) (a)
by Friedman’s test and p-values < .05 were considered statistically significant (marked red).
Only the structures, which were detected as significantly different by Friedman’s test, were fur-
ther analysed by a Wilcoxon’s post-hoc test to identify if such differences occurred as a result
of deviation from the standard procedure. (b) Wilcoxon’s test was used to compare standard
conditions with the altered conditions for plasma and serum separately. Statistical tests
between two non-standard conditions were not performed, since these are not relevant for this
study. Nine tests were performed for serum conditions, resulting in a Bonferroni corrected p
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value of .0056. For plasma conditions five tests were performed including (c) Wilcoxon’s test
where results from only 5 individuals were compared, therefore the Bonferroni corrected p
value for plasma samples was .01. The Oxford notations are: pentasaccharide core (A0) con-
sists of three mannose residues and two N-acetylglucosamines (GlcNAc); F core fucose; aF
antennary fucose; Ax, number GlcNAc attached to the core; B, bisecting GlcNAc; Gx, number
of β1–4 linked galactose (G) on antennae; [3]G1 and [6]G1 indicates that the galactose is on
the antenna of the α1–3 or α1–6 mannose. The [x] indicate the linkage type: in A2[3]G1 the
galactose is linked to the α1–3 mannose, and in A3[2,2,6] the N-acetylglucosamines are β1-2-,
β1-2-, and β1-6-linked to the trimannosyl core. In A3G3[3], the [3] indicates a β1–3 linkage
between terminal G and GlcNAc.
(PDF)
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